Additionally, we have shown that the significant increases in the proportion of CD8 + and CD4 + proliferating T-cells compared to pre-treatment values were only detected in the NSCLC patients who received SBRT with 10Gy or less per fraction. Here, CD8A is linked to non-small cell lung carcinoma.